From cursor to physical machine control
Neuralink's early public milestones focused on digital interfaces — controlling a computer cursor or playing chess using thought alone. The first recipient, Noland Arbaugh, demonstrated those capabilities publicly in early 2024. Alex Conley's case marks the next step: the brain-computer interface moves beyond the screen and routes neural signals directly to physical machines — a robotic arm and a drone.
Conley suffered spinal cord damage in a vehicle rollover accident in 2021, which caused paralysis of the lower body and confined him to a wheelchair. In July 2025, he became the second person to receive a Neuralink implant. His case had not been described in detail publicly until the TV interview.
Speaking to the Katie Pavlich Tonight programme, he described the change: "I was stuck in a chair in a room, unable to do anything. Now the robotic arm can open a door and get outside without help from a caregiver or my family."
Return to professional work through the interface
Before his accident, Conley worked as a welder and mechanic — professions centred on hands-on, physical skill. After receiving the implant, he began using computer-aided design (CAD) software to create objects again. His first documented project was a holder for the Neuralink charging device; the design was ready for 3D printing the day after he created it.
This use case goes beyond medical rehabilitation in the narrow sense. Conley did not only recover the ability to move independently — he recovered the ability to perform professional work.
He also stated a further goal: to manufacture parts for Elon Musk's spacecraft. "I'm not sure I'm qualified for that," he said, "but I'm very honoured to have been chosen as the second implant recipient."
Neuralink's clinical context and the April post
On April 24, 2026, Neuralink posted a video to X showing trial participants controlling robotic arms through thought. The caption read: "We are working to restore mobility that was lost due to disease or spinal cord injury by allowing participants to control robotic arms with their thoughts."
The company described the "primary goal of the clinical trial" as "improving hardware and the overall procedure for all participants." This framing treats individual use cases as product-iteration data, not merely proof-of-concept demonstrations.
Within two years of the first surgical procedure, the company had enrolled 21 clinical trial participants — a pace that reflects both regulatory staging and the complexity of neurosurgical intervention. By comparison, BrainGate, the academic BCI platform that predates Neuralink, has operated for over a decade with limited clinical deployment at scale.
Musk's plan: mass production and a new surgical technique
On December 31, 2025, Elon Musk announced on X plans for mass production of BCI devices, alongside a target of near-fully automated surgical procedures in 2026. The new technique would not require incising the dura mater — the outer membrane of the brain — with electrode threads passing through brain tissue without that additional step. This would significantly reduce surgical time and associated risk.
If these timelines hold, 2026 is the year Neuralink moves from technology verification to operational scaling. Automation of the surgical procedure is central to this: the current process requires a highly specialised neurosurgeon and several hours in an operating room.
Why this matters
Neuralink's demonstrations with Conley represent the first company-documented case in which BCI implants control not only digital interfaces but real physical hardware in real time. This shift is significant for several reasons.
First, it expands the potential applications beyond computer rehabilitation. Controlling prosthetics, wheelchairs, home devices, and industrial machines becomes a technically plausible product line rather than distant speculation.
Second, Conley's case shows that BCI can restore not only biological function but professional identity and economic productivity — which changes the regulatory narrative around this technology from "medical device" to something closer to "work tool".
Third, the enrolment pace (21 participants in two years) and the automation plans signal that Neuralink is treating scaling as an active operational phase, not a distant horizon. Questions about the legal frameworks, insurance coverage, and accessibility of the technology are becoming more urgent.
What's next?
- Tracking the timeline for Neuralink's automated surgical procedure in 2026 — FDA clearance will be the key milestone.
- Future clinical results should indicate whether physical device control (drones, robotic arms) becomes a standard element of trial protocols or remains an exceptional individual case.
- Questions about certification and safety standards for BCI-controlled equipment in industrial or commercial settings remain unresolved.
Sources
- AI Times (Korea)
뉴럴링크, '디지털' 넘어 '물리적 제어' 성공...마비 환자 드론 조종까지 - https://www.aitimes.com/news/articleView.html?idxno=210040 - Neuralink on X
Post from April 24, 2026 (robotic arm control) - https://twitter.com/neuralink/status/2047803749226144089 - AI Times (Korea) — clinical trial context
뉴럴링크 "2년 만에 인간 뇌 임플란트 시험 참가자 21명" - https://www.aitimes.com/news/articleView.html?idxno=206122 - AI Times (Korea) — mass production announcement
머스크 "2026년 뉴럴링크 BCI 양산...경막 제거 없는 기술 적용" - https://www.aitimes.com/news/articleView.html?idxno=205228
